I believe that this article ties in with the Octob
Post# of 30066
Posted On: 08/10/2015 2:15:11 PM
I believe that this article ties in with the October 2013 press release below. See the last sentence of the press release. Maybe a definitive agreement with Renishaw for MANF studies is forthcoming.
Amarantus BioSciences, Inc. Enters Into Letter of Intent With Renishaw plc for Convection-Enhanced Delivery of MANF in Parkinson's Disease
10/3/2013 9:56:16 AM
SUNNYVALE, Calif., Oct. 3, 2013 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to neurodegeneration and apoptosis, today announced that it has entered into a letter of intent (the "LOI"
with Renishaw PLC for the use of Renishaw's proprietary implantable neurosurgical products and systems, including the neuromate® stereotactic robot, neuroinspire™ surgical planning software, and neuroinfuse™ - intraparenchymal delivery system for the delivery of MANF in Parkinson's disease and other neurological conditions. Over the course of the next 12 months, the companies will collaborate to conduct certain feasibility studies to ensure the long-term viability of delivering MANF using Renishaw's product line to key brain structures. If successful, the companies expect to enter into a definitive agreement to support human clinical studies and commercial use .
Quote:
Great MANF article-thanks Zoomboom
http://www.jns-journal.com/article/S0022-510X...3/abstract
Amarantus BioSciences, Inc. Enters Into Letter of Intent With Renishaw plc for Convection-Enhanced Delivery of MANF in Parkinson's Disease
10/3/2013 9:56:16 AM
SUNNYVALE, Calif., Oct. 3, 2013 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to neurodegeneration and apoptosis, today announced that it has entered into a letter of intent (the "LOI"
with Renishaw PLC for the use of Renishaw's proprietary implantable neurosurgical products and systems, including the neuromate® stereotactic robot, neuroinspire™ surgical planning software, and neuroinfuse™ - intraparenchymal delivery system for the delivery of MANF in Parkinson's disease and other neurological conditions. Over the course of the next 12 months, the companies will collaborate to conduct certain feasibility studies to ensure the long-term viability of delivering MANF using Renishaw's product line to key brain structures. If successful, the companies expect to enter into a definitive agreement to support human clinical studies and commercial use . 
(0)
(0)